SMi presents the 13th annual industry leading conference: Cold Chain Distribution

SMi Group10 - 11 December 2018, London, UK.
The 13th annual event will specifically focus on recent advances in temperature-controlled logistic solutions and the impact of regulatory changes on this multi-billion-dollar industry. The event will also address the impact of the overwhelming digitalisation of the industry and how companies, from biotech’s to pharma, need to adapt, as well as the crucial challenges of supply chain visibility and data integrity in the cold chain industry.

The two-day event will also look at various developments within the industry, guiding companies on how best to ensure costs are kept low, and quality remains high, whilst simultaneously staying compliant to global regulations.

This year's event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations and issues in the field of temperature-controlled distribution.

Chairs for 2018

  • Bob Hayes, Director, SeerPharma (UK)
  • Tony Wright, CEO, Exelsius

Featured Speakers

  • Bob Hayes, Director, SeerPharma (UK)
  • Stephen Mitchell, Quality Lead Logistics Partnerships, GSK
  • GianneOlaes-Dénis, Supply Chain Quality Manager, SanofiGenzymeEurope
  • Stefan Braun, Managing Director, SmartCAE
  • GianpieroLorusso, Director, Supply Operations and GS, Merck
  • Francicso Rizzuto, Cargo Specialist, Manager for Europe, IATA
  • Marco Gaudesi, Pharmacist - GDP and Cold Chain Referent, MSF
  • Henk Mulder, Head, Digital Cargo, IATA

Key Highlights

  • Evaluate the current GDP guidelines, with reference to the recently published PQG/ECA guide and discover the implications for everyday practice
  • Explore the overwhelming digitalisation of the supply chain and identify the subsequent security issues involved
  • Discover the temperature-controlled logistic solutions to best optimize your supply chain
  • Discuss the technical agreements within the supply chain and find out what questions you should be asking
  • Identify the challenges for the supply chain within emerging markets and discover the best solutions for optimization of your process

View the full agenda online: www.coldchain-distribution.com

  • Register by 29th June and save £400
  • Register by 28th September and save £300
  • Register by 31st October and save £200

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...